Insulet (NASDAQ:PODD) Price Target Raised to $305.00 at Wells Fargo & Company

Insulet (NASDAQ:PODD) had its price objective upped by Wells Fargo & Company from $290.00 to $305.00 in a report issued on Wednesday morning,Benzinga reports. They currently have an overweight rating on the medical instruments supplier’s stock.

PODD has been the subject of a number of other reports. Piper Sandler boosted their price objective on Insulet from $230.00 to $285.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 17th. BTIG Research boosted their price target on shares of Insulet from $260.00 to $270.00 and gave the stock a “buy” rating in a report on Friday, November 8th. Canaccord Genuity Group boosted their target price on shares of Insulet from $269.00 to $304.00 and gave the stock a “buy” rating in a research note on Monday. Barclays raised their price target on Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a research note on Monday, November 11th. Finally, Raymond James increased their price objective on Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a report on Monday, October 14th. Three equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $260.88.

Insulet Trading Down 0.5 %

NASDAQ:PODD opened at $273.47 on Wednesday. Insulet has a 12-month low of $160.19 and a 12-month high of $279.40. The firm has a market cap of $19.18 billion, a PE ratio of 46.83, a price-to-earnings-growth ratio of 4.06 and a beta of 1.21. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The stock has a fifty day moving average price of $249.75 and a 200 day moving average price of $219.03.

Insider Activity

In other Insulet news, CAO Lauren Budden sold 915 shares of Insulet stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total transaction of $252,192.30. Following the transaction, the chief accounting officer now directly owns 5,733 shares of the company’s stock, valued at $1,580,129.46. The trade was a 13.76 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.47% of the company’s stock.

Hedge Funds Weigh In On Insulet

A number of hedge funds have recently made changes to their positions in the business. Sequoia Financial Advisors LLC raised its position in Insulet by 8.1% in the second quarter. Sequoia Financial Advisors LLC now owns 2,089 shares of the medical instruments supplier’s stock valued at $422,000 after purchasing an additional 157 shares during the period. Wedmont Private Capital purchased a new stake in shares of Insulet during the 2nd quarter valued at about $280,000. Wealth Enhancement Advisory Services LLC lifted its position in Insulet by 36.2% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 2,351 shares of the medical instruments supplier’s stock worth $474,000 after acquiring an additional 625 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in Insulet by 38.8% during the 2nd quarter. Assenagon Asset Management S.A. now owns 179,393 shares of the medical instruments supplier’s stock worth $36,202,000 after acquiring an additional 50,101 shares in the last quarter. Finally, Nisa Investment Advisors LLC boosted its holdings in Insulet by 90.1% in the 2nd quarter. Nisa Investment Advisors LLC now owns 3,797 shares of the medical instruments supplier’s stock worth $766,000 after acquiring an additional 1,800 shares during the period.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.